Update shared on08 Aug 2025
Fair value Decreased 8.87%The downward revision in Senseonics Holdings’ price target reflects a combination of lowered future earnings multiples and a higher discount rate, resulting in the consensus fair value estimate declining from $1.55 to $1.41.
What's in the News
- Senseonics Holdings completed a $50 million follow-on equity offering, issuing 100 million common shares at $0.50 per share with a $0.03 discount.
- The company filed for a $50 million follow-on equity offering and subsequently filed for an at-the-market $100 million follow-on equity offering.
- Entered a securities purchase agreement with Abbott Laboratories for a private placement of up to $25 million in common stock at $0.58 per share, capped at 4.99% beneficial ownership for Abbott, contingent upon the public offering.
- Provided 2025 earnings guidance, expecting $34–38 million in global net revenue, driven by Eversense 365 rollout, with anticipated doubling of the global patient base and revenue weighted toward the fourth quarter.
Valuation Changes
Summary of Valuation Changes for Senseonics Holdings
- The Consensus Analyst Price Target has fallen from $1.55 to $1.41.
- The Future P/E for Senseonics Holdings has significantly fallen from 143.61x to 128.64x.
- The Discount Rate for Senseonics Holdings has risen from 7.23% to 7.71%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.